Carregant...
Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?
Advances in tumor biology and cancer genetics have led to the development of effective targeted therapies in oncology over the past decade. However, targeted drug development for urothelial carcinoma has been slower than for some other malignancies. The path forward in drug development is through a...
Guardat en:
| Publicat a: | Am Soc Clin Oncol Educ Book |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776417/ https://ncbi.nlm.nih.gov/pubmed/23714499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/EdBook_AM.2013.33.195 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|